@lycrahelen93
Active 8 months, 3 weeks ago
After 3months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy.
Patients with prior treatment failure or partial efficacy to onabotulinumtoxinA respond to anti-CGRP mAbs. After 3 months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy. […] View